Praxis Precision Medicines Inc (PRAX)

NASDAQ
20.87
+2.30(+12.39%)
After Hours
20.87
-0.04(-0.19%)
- Real-time Data
  • Volume:
    247,752
  • Bid/Ask:
    19.31/23.57
  • Day's Range:
    18.72 - 20.93
  • Type:Equity
  • Market:United States
  • ISIN:US74006W1080
  • CUSIP:00074006W108

PRAX Overview

Prev. Close
18.57
Day's Range
18.72-20.93
Revenue
-
Open
18.72
52 wk Range
12.71-60.95
EPS
-2.79
Volume
247,752
Market Cap
830.15M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
283,227
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
44,703,775
Next Earnings Date
Dec 01, 2021
What is your sentiment on Praxis Precision Medicines Inc?
or
Market is currently closed. Voting is open during market hours.

Praxis Precision Medicines Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyNeutralSell
SummaryStrong BuyStrong BuyStrong BuyNeutralSell

Praxis Precision Medicines Inc Company Profile

Praxis Precision Medicines Inc Company Profile

Employees
67

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Read More
  • Schwab gave this an A rating this week. Wedbush target is 61. Analyst range according to Fidelity is 62 to 84 so there seems to be some good potential.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.